Genus plc (OTCMKTS:GENSF – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 49,507 shares, a growth of 32.9% from the January 29th total of 37,249 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Genus in a report on Thursday, November 20th. One analyst has rated the stock with a Buy rating, According to MarketBeat, Genus currently has a consensus rating of “Buy”.
Check Out Our Latest Analysis on Genus
Genus Stock Performance
Genus Company Profile
Genus plc, trading on the OTCMKTS under the symbol GENSF, is a global leader in innovative animal genetics and breeding solutions. The company operates through two primary business segments: ABS and PIC. ABS focuses on bovine genetics, offering dairy and beef cattle semen, advanced reproductive technologies and digital herd management tools. PIC specializes in porcine genetics, providing breeding stock, genetic evaluation services and production support aimed at optimizing growth performance, health and sustainability across the global swine industry.
With origins dating back to its establishment in 1933 as the British Dairy Cattle Breeders’ Society, Genus has expanded through strategic acquisitions and organic growth to build a leading position in animal biotechnology.
Recommended Stories
- Five stocks we like better than Genus
- America’s 1776 happening again
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- The Biggest IPO Ever… Open to Everyday Folks
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
